Pfizer announces partnership with UK university
pharmafile | March 13, 2017 | News story | Medical Communications, Sales and Marketing | Pfizer, Swansea University
Pfizer and Swansea University have announced plans to collaborate on a new Innovation Hub at Swansea University’s new £450 million Bay Campus. The initiative launches a ‘new memorandum of understanding’ that will see the university and Pfizer collaborate to initiate health initiatives across Wales.
The move will see Pfizer set up an Innovate Hub at the University, located in the School of Management on the Fabian Way campus whilst also working with the Medical School’s Institute of Life Science Enterprise and Innovation at the Singleton Campus.
Announcing the collaborative venture, Erik Nordkamp, Managing Director, Pfizer UK, said: “We’re pleased to announce our intention to collaborate with Swansea University. Partnership working between the pharmaceutical industry, academia and the NHS is essential for tackling today’s demands on the health system. Through sharing our different skills and expertise we really can make a difference to improving health outcomes for patients, and developing new ways of supporting the provision of healthcare.”
The deal comes at a time of major investment in the South West of Wales. More than £1.3 billion could be pumped into the region as part of an investment package aiming to improve the digital infrastructure and facilities in the area of health and life sciences. The so-called ‘City Deal’ will see 10,000 new jobs created, as well as attracting companies, such as Pfizer, into the region.
Professor Richard B Davies, Vice-Chancellor of Swansea University, said: “This exciting new collaboration with Pfizer, one of the world’s largest research-based biopharmaceutical companies, is part of an intensified mission of mobilising the University’s resources in support of the NHS Wales, working closely with Health Boards and the Welsh Government.”
Ben Hargreaves
Related Content
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …
Pfizer releases results for severe RSV-associated LRTD treatment study
US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical …
New Real-World Data Published in Journal of Cardiac Failure on Effectiveness
Patients treated with tafamidis were associated with greater rates of survival compared with patients untreated …
